Crewe Advisors’s ESSA Pharma EPIX Stock Holding History

Crewe Advisors’s Portfolio EPIX Stock Details EPIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-265	Closed	-$788	–	917
2023 Q1	$788	Hold	265	–	–	﹤0.01%	767
2022 Q4	$668	Hold	265	–	–	﹤0.01%	957
2022 Q3	$0	Hold	265	–	–	﹤0.01%	1250
2022 Q2	$1K	Buy	+265	New	+$1.48K	﹤0.01%	1058

Other funds holding EPIX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Crewe Advisors's EPIX Position: Q2 2023 in Review

Crewe Advisors sold out of ESSA Pharma (EPIX) in Q2 2023, closing a stake of 265 shares — an estimated $788 sold.

Crewe Advisors first reported a position in EPIX in Q2 2022 and held it in 4 quarters. The position peaked at $1K in Q2 2022. 39 funds tracked by Wall St. Rank hold EPIX as of Q2 2023.

Crewe Advisors reported no remaining ESSA Pharma position as of Q2 2023 after selling out during the quarter.
Crewe Advisors sold 265 ESSA Pharma shares in Q2 2023, an estimated $788.
Crewe Advisors first reported a position in ESSA Pharma in Q2 2022 and held it in 4 quarters.
Crewe Advisors's ESSA Pharma position peaked at $1K in Q2 2022.
39 funds tracked by Wall St. Rank held ESSA Pharma as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.